- Previous Close
0.0000 - Open
-- - Bid --
- Ask --
- Day's Range
-- - 52 Week Range
2.9474 - 2.9474 - Volume
-- - Avg. Volume
0 - Market Cap (intraday)
74.244M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. Its lead candidate is a novel antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. The company was incorporated in 2021 and is headquartered in Vancouver, Canada.
www.metherapeutics.comRecent News: METXF
View More
Performance Overview: METXF
Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: METXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: METXF
View MoreValuation Measures
Market Cap
92.83M
Enterprise Value
92.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
62.26
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Company Insights: METXF
METXF does not have Company Insights